Heron Therapeutics (HRTX) Income from Continuing Operations (2010 - 2026)
Heron Therapeutics (HRTX) reported Income from Continuing Operations of 4765000.0 for Q1 2026, down 251.08% on a YoY basis from 3154000.0 in Q1 2025, and down 12639.47% quarter-over-quarter from 38000.0 in Q4 2025.
Heron Therapeutics (HRTX) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Heron Therapeutics has reported Income from Continuing Operations for 17 years, with the latest figure at 4765000.0 in Q1 2026.
- For the quarter ending Q1 2026, Income from Continuing Operations fell 251.08% year-over-year to 4765000.0; the trailing twelve-month figure through Mar 2026 stood at 10457000.0 (down 192.42% YoY), and the FY2025 full-year result was 10195000.0, up 27.23% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 4765000.0, down from 38000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 4173000.0 in Q4 2024, with the low at 62923000.0 in Q1 2022.
- Historically, Income from Continuing Operations has averaged 17888470.59 across 5 years, with a median of 6445000.0 in 2024.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations surged 165.74% — and 2026, when it tumbled 251.08%.
- Heron Therapeutics' Income from Continuing Operations stood at 20355000.0 in 2022, then surged by 49.79% to 10220000.0 in 2023, then soared by 140.83% to 4173000.0 in 2024, then plunged by 99.09% to 38000.0 in 2025, then sank by 12639.47% to 4765000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 4765000.0 (Q1 2026), 38000.0 (Q4 2025), and 4093000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 30.80 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | -3.40 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -56.48 Mn |
| 10 | Heron Therapeutics | 85.57 Mn | 55.60 Mn | 24.07 Mn | -4.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.77 Mn |
| Dec 31, 2025 | 38,000.00 |
| Sep 30, 2025 | -4.09 Mn |
| Jun 30, 2025 | -1.64 Mn |
| Mar 31, 2025 | 3.15 Mn |
| Dec 31, 2024 | 4.17 Mn |
| Sep 30, 2024 | -4.46 Mn |
| Jun 30, 2024 | -6.45 Mn |
| Mar 31, 2024 | -4.80 Mn |
| Dec 31, 2023 | -10.22 Mn |
| Sep 30, 2023 | -24.93 Mn |
| Jun 30, 2023 | -42.40 Mn |
| Mar 31, 2023 | -33.06 Mn |
| Dec 31, 2022 | -20.36 Mn |
| Sep 30, 2022 | -41.88 Mn |
| Jun 30, 2022 | -49.50 Mn |
| Mar 31, 2022 | -62.92 Mn |
| Dec 31, 2021 | -53.54 Mn |
| Sep 30, 2021 | -51.71 Mn |
| Jun 30, 2021 | -60.47 Mn |